[
  {
    "ts": null,
    "headline": "The Inner Circle Acknowledges Dr. David Thrasher as a Pinnacle Professional for Leadership in Healthcare and Public Service",
    "summary": "Alabama recently announced the largest single investment in state history. Eli Lilly, the world's most valuable pharmaceutical company, plans to build a $6 billion advanced manufacturing facility in Huntsville. Governor Ivey, Commerce Secretary McNair, Mayor Battle, U.S. Senators Britt and Tuberville, State Senator Givhan worked to make this vision a reality.",
    "url": "https://finnhub.io/api/news?id=e2bf603aeb342337f977df5aaf66b4b139954f0344e70ddaf80a36924c8350d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768934100,
      "headline": "The Inner Circle Acknowledges Dr. David Thrasher as a Pinnacle Professional for Leadership in Healthcare and Public Service",
      "id": 138189460,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Alabama recently announced the largest single investment in state history. Eli Lilly, the world's most valuable pharmaceutical company, plans to build a $6 billion advanced manufacturing facility in Huntsville. Governor Ivey, Commerce Secretary McNair, Mayor Battle, U.S. Senators Britt and Tuberville, State Senator Givhan worked to make this vision a reality.",
      "url": "https://finnhub.io/api/news?id=e2bf603aeb342337f977df5aaf66b4b139954f0344e70ddaf80a36924c8350d0"
    }
  },
  {
    "ts": null,
    "headline": "Which Pharma Stock Stands Taller Right Now: LLY or PFE?",
    "summary": "Eli Lilly's Mounjaro and Zepbound fuel rapid growth as new launches and an oral GLP-1 near approval shape its investment case against peers.",
    "url": "https://finnhub.io/api/news?id=ee6e7705b683cddfed586b09c3c6466ee59108c6304fbf023f2979bd386e7293",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768914480,
      "headline": "Which Pharma Stock Stands Taller Right Now: LLY or PFE?",
      "id": 138187432,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's Mounjaro and Zepbound fuel rapid growth as new launches and an oral GLP-1 near approval shape its investment case against peers.",
      "url": "https://finnhub.io/api/news?id=ee6e7705b683cddfed586b09c3c6466ee59108c6304fbf023f2979bd386e7293"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received prior bevacizumab and mirvetuximab soravtansine, if eligible. Sofetabart mipitecan is a novel folate receptor alpha (FRα) antibody-drug conjugate (ADC) that uses proprietary li",
    "url": "https://finnhub.io/api/news?id=3b5d516e70a259ef81f93dd255e76c3c20935b6050e6e6f83b7d27975cd82643",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768913100,
      "headline": "Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer",
      "id": 138186414,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received prior bevacizumab and mirvetuximab soravtansine, if eligible. Sofetabart mipitecan is a novel folate receptor alpha (FRα) antibody-drug conjugate (ADC) that uses proprietary li",
      "url": "https://finnhub.io/api/news?id=3b5d516e70a259ef81f93dd255e76c3c20935b6050e6e6f83b7d27975cd82643"
    }
  },
  {
    "ts": null,
    "headline": "CURE: Benefits And Caveats Of The Leveraged Healthcare ETF",
    "summary": "Direxion CURE ETF offers 3x daily healthcare exposureâlearn risks like volatility decay and drift, plus tactical trading tips using XLV/index signals.",
    "url": "https://finnhub.io/api/news?id=ca3612c5b4891b901620bb4fdb6c38f001242d9ac0824dccbf1890b2577a24b9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768912790,
      "headline": "CURE: Benefits And Caveats Of The Leveraged Healthcare ETF",
      "id": 138188296,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1351287260/image_1351287260.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Direxion CURE ETF offers 3x daily healthcare exposureâlearn risks like volatility decay and drift, plus tactical trading tips using XLV/index signals.",
      "url": "https://finnhub.io/api/news?id=ca3612c5b4891b901620bb4fdb6c38f001242d9ac0824dccbf1890b2577a24b9"
    }
  },
  {
    "ts": null,
    "headline": "Texas, N. Carolina, Ohio, Pennsylvania — where pharma manufacturing investments have surged",
    "summary": "Pledged projects have landed in a handful of hotspots while giving rise to potential new hubs across the U.S.",
    "url": "https://finnhub.io/api/news?id=29eb1b73de3a68aad76b4ce27ece84f3cb32f6b1356d04dcd510e0c438ca2f2b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768895656,
      "headline": "Texas, N. Carolina, Ohio, Pennsylvania — where pharma manufacturing investments have surged",
      "id": 138186415,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pledged projects have landed in a handful of hotspots while giving rise to potential new hubs across the U.S.",
      "url": "https://finnhub.io/api/news?id=29eb1b73de3a68aad76b4ce27ece84f3cb32f6b1356d04dcd510e0c438ca2f2b"
    }
  },
  {
    "ts": null,
    "headline": "Zacks Market Edge Highlights: TSLA, NVDA and LLY",
    "summary": "Is the Magnificent 7 finished? NVDA shines while Tesla struggles and Eli Lilly surges, as Zacks Market Edge debates who stays, who goes in 2026.",
    "url": "https://finnhub.io/api/news?id=1c0f287731322ab627cb853003bfd60770989a3aa5c0a5843ce4ca0f6157b91b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768894860,
      "headline": "Zacks Market Edge Highlights: TSLA, NVDA and LLY",
      "id": 138185012,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Is the Magnificent 7 finished? NVDA shines while Tesla struggles and Eli Lilly surges, as Zacks Market Edge debates who stays, who goes in 2026.",
      "url": "https://finnhub.io/api/news?id=1c0f287731322ab627cb853003bfd60770989a3aa5c0a5843ce4ca0f6157b91b"
    }
  },
  {
    "ts": null,
    "headline": "How Investors May Respond To NVIDIA (NVDA) Expanding Its AI Platform From Gaming To Drug Discovery",
    "summary": "NVIDIA and its partners have, over recent days, unveiled a wave of new AI hardware and collaborations, from Blackwell-based GeForce RTX 5090 gaming cards and Vera Rubin data center systems to deep-life-sciences tie‑ups with Eli Lilly, Natera, Thermo Fisher and others built on the NVIDIA AI platform. Together, these launches and alliances extend NVIDIA’s AI reach from gaming and autonomous vehicles to drug discovery, industrial automation and privacy-first cloud infrastructure, reinforcing...",
    "url": "https://finnhub.io/api/news?id=4242df3b587e1f1967ec463f3f2233e8d06913f6830267c6b88bf125a941e17d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768889451,
      "headline": "How Investors May Respond To NVIDIA (NVDA) Expanding Its AI Platform From Gaming To Drug Discovery",
      "id": 138184341,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVIDIA and its partners have, over recent days, unveiled a wave of new AI hardware and collaborations, from Blackwell-based GeForce RTX 5090 gaming cards and Vera Rubin data center systems to deep-life-sciences tie‑ups with Eli Lilly, Natera, Thermo Fisher and others built on the NVIDIA AI platform. Together, these launches and alliances extend NVIDIA’s AI reach from gaming and autonomous vehicles to drug discovery, industrial automation and privacy-first cloud infrastructure, reinforcing...",
      "url": "https://finnhub.io/api/news?id=4242df3b587e1f1967ec463f3f2233e8d06913f6830267c6b88bf125a941e17d"
    }
  },
  {
    "ts": null,
    "headline": "The Bull Case For Illumina (ILMN) Could Change Following Its Billion Cell Atlas Pharma Alliance",
    "summary": "Earlier in January 2026, Illumina announced the Billion Cell Atlas alliance with AstraZeneca, Merck, and Eli Lilly, alongside new AI‑enabled genomics and multiomics platforms that integrate CRISPR, single-cell sequencing, and cloud analytics to support drug discovery and precision medicine. This push into large-scale genomics datasets and multiomic software marks a shift toward data-driven services that could reshape how Illumina works with pharmaceutical partners across the drug development...",
    "url": "https://finnhub.io/api/news?id=d20e84e98bba094dc7b7621bd83937b07ee3b91361cccee898537fbfe250fdb1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768889399,
      "headline": "The Bull Case For Illumina (ILMN) Could Change Following Its Billion Cell Atlas Pharma Alliance",
      "id": 138184366,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Earlier in January 2026, Illumina announced the Billion Cell Atlas alliance with AstraZeneca, Merck, and Eli Lilly, alongside new AI‑enabled genomics and multiomics platforms that integrate CRISPR, single-cell sequencing, and cloud analytics to support drug discovery and precision medicine. This push into large-scale genomics datasets and multiomic software marks a shift toward data-driven services that could reshape how Illumina works with pharmaceutical partners across the drug development...",
      "url": "https://finnhub.io/api/news?id=d20e84e98bba094dc7b7621bd83937b07ee3b91361cccee898537fbfe250fdb1"
    }
  },
  {
    "ts": null,
    "headline": "Assessing Eli Lilly (LLY) Valuation After Recent Choppy Trading And GLP 1 Growth Expectations",
    "summary": "Stock performance context for Eli Lilly (LLY) Eli Lilly (LLY) has drawn fresh attention after recent price moves, with the share closing at $1,038.40. Short term returns have been mixed, while longer periods show stronger total return figures. See our latest analysis for Eli Lilly. Recent trading has been choppy, with a 7 day share price return of a 3.94% decline and a 30 day share price return of a 3.08% decline, while the 90 day share price return of 29.87% and 1 year total shareholder...",
    "url": "https://finnhub.io/api/news?id=aaf6f03d14f2d147498751c3a90c5e254ce7236fb2eb9ff59399e6db4f13972a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768867886,
      "headline": "Assessing Eli Lilly (LLY) Valuation After Recent Choppy Trading And GLP 1 Growth Expectations",
      "id": 138181934,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Stock performance context for Eli Lilly (LLY) Eli Lilly (LLY) has drawn fresh attention after recent price moves, with the share closing at $1,038.40. Short term returns have been mixed, while longer periods show stronger total return figures. See our latest analysis for Eli Lilly. Recent trading has been choppy, with a 7 day share price return of a 3.94% decline and a 30 day share price return of a 3.08% decline, while the 90 day share price return of 29.87% and 1 year total shareholder...",
      "url": "https://finnhub.io/api/news?id=aaf6f03d14f2d147498751c3a90c5e254ce7236fb2eb9ff59399e6db4f13972a"
    }
  }
]